MoneyMarkets Athersys gets FDA OK for phase 2/3 to study MultiStem in patients with COVID-19-induced ARDS By Market Watch - April 13, 2020 0 135 Share Facebook Twitter Google+ Pinterest WhatsApp This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news. Source : MTV